Notícias Teva Pharmaceutical Industries Ltd - TEVA | Ações New York Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Teva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Ltd (TEVA) Notícias

Teva Pharmaceutical Industries Ltd (TEVA)

16,63

0,29

(1,77%)

No fechamento: 13 Fevereiro 6:00PM

Atrasado por 15 minutos

16,70

0,07

( 0,42% )

Após o horário de negociação: 9:45PM

Atrasado por 15 minutos

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

Teva to Present at the 2024 Bank of America Healthcare Conference

Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

3
4
5
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Teva Pharmaceutical Indu...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições